Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis - PubMed (original) (raw)
. 2006 Aug 25;281(34):24449-54.
doi: 10.1074/jbc.M605200200. Epub 2006 Jun 30.
Affiliations
- PMID: 16816386
- DOI: 10.1074/jbc.M605200200
Free article
Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis
Xinhua Chen et al. J Biol Chem. 2006.
Free article
Abstract
Saccharomyces boulardii (Sb), a probiotic yeast, protects against intestinal injury and inflammation caused by a wide variety of enteric pathogens, including Clostridium difficile. Given the broad range of protective effects of Sb in multiple gastrointestinal disorders, we hypothesize that Sb modulates host signaling pathways involved in intestinal inflammatory responses. In this study, we found that Sb culture supernatant (SbS) inhibits interleukin-8 production induced by C. difficile toxin A or IL-1beta in human colonocyte NCM460 cells in a dose-dependent fashion. Furthermore, SbS inhibited IL-1beta and toxin A induced Erk1/2 and JNK/SAPK but not p38 activation in NCM460 cells. To test whether this inhibition also occurs in vivo, we used a previously established mouse ileal loop model. On its own, SbS had no significant effect on basal fluid secretion or intestinal histology. However, Erk1/2 activation was significantly inhibited by SbS in toxin A exposed mouse ileal mucosa. In control loops, toxin A increased fluid secretion (2.2-fold), histological score (3.3-fold), and levels of the chemokine KC (4.5-fold). SbS pretreatment completely normalized toxin A mediated fluid secretion (p < 0.01), and histopathologic changes (p < 0.01) and substantially inhibited toxin A-associated KC increases (p < 0.001). In summary, the probiotic yeast S. boulardii inhibits C. difficile toxin A-associated enteritis by blocking the activation of Erk1/2 MAP kinases. This study indicates a new mechanism whereby Sb protects against intestinal inflammation and supports the hypothesis that Sb modulates host inflammatory signaling pathways to exert its beneficial effects.
Similar articles
- Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Castagliuolo I, et al. Infect Immun. 1999 Jan;67(1):302-7. doi: 10.1128/IAI.67.1.302-307.1999. Infect Immun. 1999. PMID: 9864230 Free PMC article. - Effects of transcription factor activator protein-1 on interleukin-8 expression and enteritis in response to Clostridium difficile toxin A.
Lee JY, Park HR, Oh YK, Kim YJ, Youn J, Han JS, Kim JM. Lee JY, et al. J Mol Med (Berl). 2007 Dec;85(12):1393-404. doi: 10.1007/s00109-007-0237-7. Epub 2007 Jul 18. J Mol Med (Berl). 2007. PMID: 17639289 - p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis.
Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JK, Aboudola S, Qamar A, Pothoulakis C, LaMont JT, Kelly CP. Warny M, et al. J Clin Invest. 2000 Apr;105(8):1147-56. doi: 10.1172/JCI7545. J Clin Invest. 2000. PMID: 10772660 Free PMC article. - [Recent advances in Saccharomyces boulardii research].
Im E, Pothoulakis C. Im E, et al. Gastroenterol Clin Biol. 2010 Sep;34 Suppl 1:S62-70. doi: 10.1016/S0399-8320(10)70023-3. Gastroenterol Clin Biol. 2010. PMID: 20889007 Review. French. - Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.
Pothoulakis C. Pothoulakis C. Aliment Pharmacol Ther. 2009 Oct 15;30(8):826-33. doi: 10.1111/j.1365-2036.2009.04102.x. Epub 2008 Jul 23. Aliment Pharmacol Ther. 2009. PMID: 19706150 Free PMC article. Review.
Cited by
- Probiotics-host communication: Modulation of signaling pathways in the intestine.
Thomas CM, Versalovic J. Thomas CM, et al. Gut Microbes. 2010 May-Jun;1(3):148-63. doi: 10.4161/gmic.1.3.11712. Gut Microbes. 2010. PMID: 20672012 Free PMC article. Review. - Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection.
Martins FS, Dalmasso G, Arantes RM, Doye A, Lemichez E, Lagadec P, Imbert V, Peyron JF, Rampal P, Nicoli JR, Czerucka D. Martins FS, et al. PLoS One. 2010 Jan 27;5(1):e8925. doi: 10.1371/journal.pone.0008925. PLoS One. 2010. PMID: 20111723 Free PMC article. - Inhibition of In Vitro Clostridioides difficile Biofilm Formation by the Probiotic Yeast Saccharomyces boulardii CNCM I-745 through Modification of the Extracellular Matrix Composition.
Lacotte PA, Simons A, Bouttier S, Malet-Villemagne J, Nicolas V, Janoir C. Lacotte PA, et al. Microorganisms. 2022 May 24;10(6):1082. doi: 10.3390/microorganisms10061082. Microorganisms. 2022. PMID: 35744599 Free PMC article. - Probiotics: insights and new opportunities for Clostridioides difficile intervention.
Pal R, Athamneh AIM, Deshpande R, Ramirez JAR, Adu KT, Muthuirulan P, Pawar S, Biazzo M, Apidianakis Y, Sundekilde UK, de la Fuente-Nunez C, Martens MG, Tegos GP, Seleem MN. Pal R, et al. Crit Rev Microbiol. 2023 May;49(3):414-434. doi: 10.1080/1040841X.2022.2072705. Epub 2022 May 15. Crit Rev Microbiol. 2023. PMID: 35574602 Free PMC article. Review. - Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.
Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Hudson LE, et al. Clin Microbiol Rev. 2017 Jan;30(1):191-231. doi: 10.1128/CMR.00049-16. Clin Microbiol Rev. 2017. PMID: 27856521 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous